At a glance
- Originator Eisai Co Ltd
- Class
- Mechanism of Action ACE inhibitors; Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Hypertension
Most Recent Events
- 18 Apr 2000 Preclinical development for Congestive heart failure in Japan (Unknown route)
- 18 Apr 2000 Preclinical development for Hypertension in Japan (Unknown route)